These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19127121)

  • 1. Combination therapy with TRAIL: Recent developments and potential pitfalls.
    Voelkel-Johnson C
    Cancer Biol Ther; 2009 Jan; 8(1):81-3. PubMed ID: 19127121
    [No Abstract]   [Full Text] [Related]  

  • 2. Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo.
    Christian PA; Thorpe JA; Schwarze SR
    Cancer Biol Ther; 2009 Jan; 8(1):73-80. PubMed ID: 19029816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link.
    Fulda S
    Oncotarget; 2011 May; 2(5):418-21. PubMed ID: 21789791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
    Brooks AD; Jacobsen KM; Li W; Shanker A; Sayers TJ
    Mol Cancer Res; 2010 May; 8(5):729-38. PubMed ID: 20442297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
    An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
    Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex.
    Koschny R; Boehm C; Sprick MR; Haas TL; Holland H; Xu LX; Krupp W; Mueller WC; Bauer M; Koschny T; Keller M; Sinn P; Meixensberger J; Walczak H; Ganten TM
    J Neuropathol Exp Neurol; 2014 Nov; 73(11):1034-46. PubMed ID: 25289891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?
    de Wilt LH; Kroon J; Jansen G; de Jong S; Peters GJ; Kruyt FA
    Crit Rev Oncol Hematol; 2013 Mar; 85(3):363-72. PubMed ID: 22944363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window.
    Koschny R; Ganten TM; Sykora J; Haas TL; Sprick MR; Kolb A; Stremmel W; Walczak H
    Hepatology; 2007 Mar; 45(3):649-58. PubMed ID: 17326159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
    Voortman J; Resende TP; Abou El Hassan MA; Giaccone G; Kruyt FA
    Mol Cancer Ther; 2007 Jul; 6(7):2103-12. PubMed ID: 17620439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL.
    Lu G; Punj V; Chaudhary PM
    Cancer Biol Ther; 2008 Apr; 7(4):603-8. PubMed ID: 18223318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bortezomib].
    Simons S; Scheulen ME; Jaehde U
    Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
    [No Abstract]   [Full Text] [Related]  

  • 12. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.
    Ndozangue-Touriguine O; Sebbagh M; Mérino D; Micheau O; Bertoglio J; Bréard J
    Oncogene; 2008 Oct; 27(46):6012-22. PubMed ID: 18560353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis.
    Koschny R; Holland H; Sykora J; Erdal H; Krupp W; Bauer M; Bockmuehl U; Ahnert P; Meixensberger J; Stremmel W; Walczak H; Ganten TM
    J Neurooncol; 2010 Apr; 97(2):171-85. PubMed ID: 19768634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib synergizes TRAIL-induced apoptosis in gastric cancer cells.
    Liu J; Qu XJ; Xu L; Zang Y; Qu JL; Hou KZ; Liu YP
    Dig Dis Sci; 2010 Dec; 55(12):3361-8. PubMed ID: 20393880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
    Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Velcade displays promising activity in primary effusion lymphoma cells.
    McConkey D; Nawrocki ST; Andtbacka R
    Cancer Biol Ther; 2005 Apr; 4(4):491-2. PubMed ID: 15908793
    [No Abstract]   [Full Text] [Related]  

  • 17. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
    Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS
    Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
    Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
    Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
    Seol DW
    Biochem Biophys Res Commun; 2011 Dec; 416(1-2):222-5. PubMed ID: 22120628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of bortezomib-induced apoptosis by red blood cell uptake.
    Wheat LM; Kohlhaas SL; Monbaliu J; De Coster R; Majid A; Walewska RJ; Dyer MJ
    Leukemia; 2006 Sep; 20(9):1646-9. PubMed ID: 16791268
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.